Exchange: NASDAQ·Updated 07:30 PM EST

ACRV News

News
all
press releases
Acrivon Therapeutics (NASDAQ:ACRV) Stock Lifted to Hold by Wall Street Zen
Wall Street Zen raised shares of Acrivon Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday...
MarketBeat
Acrivon Therapeutics (NASDAQ:ACRV) Stock Lifted to Hold by Wall Street Zen
Wall Street Zen raised shares of Acrivon Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday...
MarketBeat
More News
Citizens Jmp reissued a "market outperform" rating on shares of Acrivon Therapeutics in a report on Tuesday...
MarketBeat
Acrivon Therapeutics, Inc. (ACRV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
Zacks
Does Acrivon Therapeutics, Inc. (ACRV) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks
Acrivon Therapeutics (NASDAQ:ACRV) will be releasing its Q1 2026 earnings before the market opens on Wednesday, May 13. (View Earnings Report at...
MarketBeat
Shares of Acrivon Therapeutics, Inc. (NASDAQ:ACRV - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the six brokerages that are covering the company, Marketbeat.com...
MarketBeat
Acrivon Therapeutics (NASDAQ:ACRV) Trading Up 3.2% - Should You Buy...
MarketBeat
Acrivon Therapeutics, Inc. (NASDAQ:ACRV - Free Report) - Stock analysts at HC Wainwright raised their Q1 2026 earnings per share estimates for shares of Acrivon Therapeutics in a research report issued on Thursday, March 19th. HC Wainwright analyst E. Bodnar now forecasts that the company will earn...
MarketBeat
Acrivon Therapeutics, Inc. (NASDAQ:ACRV - Get Free Report) has been given a consensus rating of "Moderate Buy" by the seven analysts that are currently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold ratin...
MarketBeat

Advertisement|Remove ads.